Terns Pharmaceuticals, Inc. Stock Price, News & Analysis

Terns Pharmaceuticals, a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker TERN, announced its participation in two major investor conferences in June 2024. Senior management will present at the Jefferies Global Healthcare Conference on June 5 at 5:00 p.m. ET in New York City, and at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11 at 3:20 p.m. ET in Miami. Both events will feature fireside chats, with live webcasts available on the Terns Pharmaceuticals investor relations webpage. Replays of these webcasts will be archived for at least 30 days.

Terns Pharmaceuticals, a clinical-stage biopharmaceutical company focusing on oncology and obesity, will participate in a virtual fireside chat at UBS Obesity Therapeutics Day on May 23, 2024. The event, which will include members of Terns' senior management, will be webcast live at 1:00 p.m. ET and archived for 30 days on their investor relations page.

Terns Pharmaceuticals, Inc. reported its first quarter 2024 financial results and corporate updates, highlighting the progress on its two lead programs, TERN-701 for CML and TERN-601 for obesity. The company has a cash position of $241 million expected to last into 2026. Recent developments include positive findings from the Phase 1 study of TERN-701 and the progress of TERN-601's first-in-human trial. The company also announced key appointments in its leadership team. Financially, Terns reported a net loss of $22.4 million for Q1 2024, with R&D expenses of $18.6 million and G&A expenses of $6.9 million.

Terns Pharmaceuticals, Inc. announced the appointment of Scott Harris as chief development officer and the departure of Erin Quirk, M.D., president, head of research and development. Dr. Quirk will be leaving the company to pursue other opportunities. Mr. Harris will oversee various operations, and key executives will now report directly to the CEO. The company expressed gratitude to Dr. Quirk for her contributions and confidence in the leadership team's ability to advance their pipeline. Mr. Harris brings over 25 years of experience in drug development and is optimistic about Terns' future.

Terns Pharmaceuticals, a clinical-stage biopharmaceutical company, will participate in The Citizens JMP Life Sciences Conference 2024. Senior management will join a fireside chat to discuss the company's small-molecule product candidates for serious diseases like oncology and obesity. The event will be live webcasted on May 14, 2024, at 1:30 p.m. ET, with a replay available for 30 days.

Terns Pharmaceuticals, Inc. announced the granting of an equity inducement award to Melita Sun Jung, the new Chief Business Officer, under the terms of the Inducement Plan. The award includes an option to purchase 475,000 shares of Terns common stock at an exercise price of $5.08 per share, with a 10-year term and vesting over four years.

Terns Pharmaceuticals, a biopharmaceutical company, announces positive data from a Phase 1 study of TERN-701, a potential BCR-ABL inhibitor for CML treatment, showing no food effect on dosing. The ongoing study in healthy volunteers displayed promising results, supporting once-daily dosing with or without food. The company aims to differentiate TERN-701 from the current standard, asciminib, by offering more convenient dosing options. Phase 1 CARDINAL trial is ongoing, with interim data expected in late 2024.